公开(公告)号：US20240279220A1

公开(公告)日：2024-08-22

申请号：US18593686

申请日：2024-03-01

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Sukanthini Thurairatnam ,  Bradford Hirth ,  Zhongli Gao ,  Gregory Hurlbut ,  David Borcherding ,  Matthieu Barrague ,  Timothy Alan Gillespy ,  Alexandre Gross ,  Andrew Good ,  Roy Vaz ,  Jinyu Liu ,  Yi Li ,  Markus Metz ,  Anatoly Ruvinsky ,  Claude Barberis

IPC: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/6503

CPC classification number: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/65031

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20240239784A1

公开(公告)日：2024-07-18

申请号：US18593643

申请日：2024-03-01

Applicant: GENZYME CORPORATION

Inventor： Junkai Liao ,  Mark Munson ,  Sukanthini Thurairatnam ,  Bradford Hirth ,  Zhongli Gao ,  Gregory Hurlbut ,  David Borcherding ,  Matthieu Barrague ,  Timothy Alan Gillespy ,  Alexandre Gross ,  Thaddeus Nieduzak ,  Andrew Good ,  Roy Vaz ,  Jinyu Liu ,  Yi Li ,  Markus Metz ,  Anatoly Ruvinsky ,  Michael Kothe

IPC: C07D413/14 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.